Lyell Immunopharma Launches Phase 3 Head-to-Head CAR T-Cell Therapy Trial in Large B-Cell Lymphoma
Reuters
Nov 13, 2025
<a href="https://laohu8.com/S/LYEL">Lyell Immunopharma</a> Launches Phase 3 Head-to-Head CAR T-Cell Therapy Trial in Large B-Cell Lymphoma
Lyell Immunopharma Inc. announced updates on its next-generation CAR T-cell therapy programs, including new developments in its clinical pipeline. The company reported that it will present new clinical and translational data from its Phase 1/2 clinical trial of ronde-cel for the treatment of aggressive large B-cell lymphoma at the upcoming ASH 67th Annual Meeting and Exposition in December. Additionally, Lyell has initiated the PiNACLE - H2H, a Phase 3 head-to-head CAR T-cell therapy clinical trial in the second-line (2L) setting for aggressive large B-cell lymphoma, with enrollment expected to begin by early 2026. The company also acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate, which has shown a 67% overall response rate and an 83% disease control rate with a manageable safety profile in an ongoing U.S. Phase 1 clinical trial in patients with refractory metastatic colorectal cancer. The next data update from this trial is anticipated in the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574400-en) on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.